TerminatedNCT01987960
Brexpiprazole for PTSD
Medication studyAges 18–65Multiple countries
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Los Angeles and 58 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateDecember 2013
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 417
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Estonia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01987960
- Official title
Show the full official title
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles, United States · Riverside, United States · San Diego, United States
48 more locations
- Bradenton, United States
- Gainesville, United States
- Jacksonville, United States
- North Miami, United States
- Tampa, United States
- Indianapolis, United States
- Roslindale, United States
- Las Vegas, United States
- Nashua, United States
- The Bronx, United States
- Cincinnati, United States
- Dayton, United States
- Portland, United States
- Norristown, United States
- Memphis, United States
- Austin, United States
- Seattle, United States
- Tallinn, Estonia
- Helsinki, Finland
- Kuopio, Finland
- Oulu, Finland
- Tampere, Finland
- Turku, Finland
- Fort de France, France
- Laxou, France
- Nîmes, France
- Thuir, France
- Tours, France
- Andria, Italy
- Catania, Italy
- Lecce, Italy
- Pisa, Italy
- Siena, Italy
- Bialystok, Poland
- Gdansk, Poland
- Leszno, Poland
- Lublin, Poland
- Belgrade, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Bloemfontein, South Africa
- Cape Town, South Africa
- Durban, South Africa
- Port Elizabeth, South Africa
- Pretoria, South Africa
- Falun, Sweden
- Stockholm, Sweden
- Uppsala, Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Does this study involve medication?
Yes. The study involves medication, including Placebo and Brexpiprazole.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
